Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase.

Antimicrob Agents Chemother

Antimicrobial Research Centre and Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.

Published: October 2010

Previous studies suggest that furanyl-rhodanines might specifically inhibit bacterial RNA polymerase (RNAP). We further explored three compounds from this class. Although they inhibited RNAP, each compound also inhibited malate dehydrogenase and chymotrypsin. Using biosensors responsive to inhibition of macromolecular synthesis and membrane damaging assays, we concluded that in bacteria, one compound inhibited DNA synthesis and another caused membrane damage. The third rhodanine lacked antibacterial activity. We consider furanyl-rhodanines to be unattractive RNAP inhibitor drug candidates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944609PMC
http://dx.doi.org/10.1128/AAC.00753-10DOI Listing

Publication Analysis

Top Keywords

furanyl-rhodanines unattractive
8
drug candidates
8
bacterial rna
8
rna polymerase
8
compound inhibited
8
unattractive drug
4
candidates development
4
development inhibitors
4
inhibitors bacterial
4
polymerase previous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!